Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes.

Yang Y, Yan Z, Wei D, Zhong J, Liu L, Zhang L, Wang F, Wei X, Xie C, Lu W, He D.

Nanotechnology. 2013 Oct 11;24(40):405101. doi: 10.1088/0957-4484/24/40/405101. Epub 2013 Sep 12.

PMID:
24029287
2.

Self-Assembled Tumor-Penetrating Peptide-Modified Poly(l-γ-glutamylglutamine)-Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma.

Yu J, Sun L, Zhou J, Gao L, Nan L, Zhao S, Peng T, Han L, Wang J, Lu W, Zhang L, Wang Y, Yan Z, Yu L.

Bioconjug Chem. 2017 Nov 15;28(11):2823-2831. doi: 10.1021/acs.bioconjchem.7b00519. Epub 2017 Oct 10.

PMID:
28968068
3.

Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.

Wei X, Gao J, Zhan C, Xie C, Chai Z, Ran D, Ying M, Zheng P, Lu W.

J Control Release. 2015 Nov 28;218:13-21. doi: 10.1016/j.jconrel.2015.09.059. Epub 2015 Sep 30.

PMID:
26428462
4.

Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.

Herringson TP, Altin JG.

Int J Pharm. 2011 Jun 15;411(1-2):206-14. doi: 10.1016/j.ijpharm.2011.03.044. Epub 2011 Apr 4.

PMID:
21443937
5.

The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.

Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q.

Int J Nanomedicine. 2013;8:2473-85. doi: 10.2147/IJN.S46962. Epub 2013 Jul 15.

6.

Targeted gene delivery to glioblastoma using a C-end rule RGERPPR peptide-functionalised polyethylenimine complex.

Wang J, Lei Y, Xie C, Lu W, Yan Z, Gao J, Xie Z, Zhang X, Liu M.

Int J Pharm. 2013 Dec 15;458(1):48-56. doi: 10.1016/j.ijpharm.2013.10.017. Epub 2013 Oct 19.

PMID:
24144951
7.

Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.

Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q.

J Control Release. 2011 Jun 30;152(3):402-10. doi: 10.1016/j.jconrel.2011.03.014. Epub 2011 Mar 22.

PMID:
21435361
8.

Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue.

Yan Z, Yang Y, Wei X, Zhong J, Wei D, Liu L, Xie C, Wang F, Zhang L, Lu W, He D.

Mol Pharm. 2014 Jan 6;11(1):218-25. doi: 10.1021/mp400393a. Epub 2013 Dec 18.

PMID:
24325555
9.

Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme.

Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR.

Mol Cancer Ther. 2006 Dec;5(12):3162-9.

10.

Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.

Yuan W, Kuai R, Ran R, Fu L, Yang Y, Qin Y, Liu Y, Tang J, Fu H, Zhang Q, Yuan M, Zhang Z, Gao F, He Q.

J Biomed Nanotechnol. 2014 Aug;10(8):1563-73.

PMID:
25016656
11.

A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.

Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G.

Int J Nanomedicine. 2014 Sep 29;9:4581-95. doi: 10.2147/IJN.S69115. eCollection 2014.

12.

Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.

Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, Yao X, Wang C, Zhang WQ, Zhang X, Zhang Q.

J Control Release. 2016 Jan 28;222:56-66. doi: 10.1016/j.jconrel.2015.12.006. Epub 2015 Dec 9.

PMID:
26682502
13.

Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.

Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W.

J Control Release. 2010 Apr 2;143(1):136-42. doi: 10.1016/j.jconrel.2009.12.020. Epub 2010 Jan 7.

PMID:
20056123
14.

Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model.

Madhankumar AB, Slagle-Webb B, Wang X, Yang QX, Antonetti DA, Miller PA, Sheehan JM, Connor JR.

Mol Cancer Ther. 2009 Mar;8(3):648-54. doi: 10.1158/1535-7163.MCT-08-0853. Epub 2009 Mar 10.

15.

PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.

Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X.

Biomaterials. 2014 May;35(14):4368-81. doi: 10.1016/j.biomaterials.2014.01.076. Epub 2014 Feb 22.

PMID:
24565519
16.

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting.

Chen FY, Yan JJ, Yi HX, Hu FQ, Du YZ, Yuan H, You J, Zhao MD.

Int J Nanomedicine. 2014 Sep 26;9:4597-608. doi: 10.2147/IJN.S69572. eCollection 2014.

17.

Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.

Shahin M, Soudy R, Aliabadi HM, Kneteman N, Kaur K, Lavasanifar A.

Biomaterials. 2013 May;34(16):4089-97. doi: 10.1016/j.biomaterials.2013.02.019. Epub 2013 Mar 5.

PMID:
23465829
18.

LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.

Yan Z, Wang F, Wen Z, Zhan C, Feng L, Liu Y, Wei X, Xie C, Lu W.

J Control Release. 2012 Jan 10;157(1):118-25. doi: 10.1016/j.jconrel.2011.07.034. Epub 2011 Jul 29.

PMID:
21827801
19.

Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.

Zhang Y, Huang Y, Zhang P, Gao X, Gibbs RB, Li S.

Int J Nanomedicine. 2012;7:4473-85. doi: 10.2147/IJN.S31981. Epub 2012 Aug 13.

20.

The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.

Gao W, Lin Z, Chen M, Yang X, Cui Z, Zhang X, Yuan L, Zhang Q.

Int J Nanomedicine. 2014 Jul 21;9:3425-37. doi: 10.2147/IJN.S56070. eCollection 2014.

Supplemental Content

Support Center